Arformoterol/Budesonide for COVID-19

• Status: Not yet recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study to evaluate the efficacy and safety of UI030 in COVID-19 patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea United Pharm. Inc.

Criteria

Inclusion Criteria:

• Adult, aged 19 years or above

• New onset of symptoms suggestive of COVID-19 (fever, cough, soar throat, etc) or diagnosed with COVID-19 within 7 days of participant being seen at visit 1

• In the Investigator's opinion, is able and willing to comply with all trial requirements

Exclusion Criteria:

• A condition requiring invasive oxygen support;

• History of hypersensitivity to budesonide and arformoterol

• Pregnancy, Breast-feeding

• Participation in other clinical studies within 4 weeks prior to enrollment in this study.

• Refusal of the patient to continue participating in the study/withdrawal of informed consent by the patient.